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Background: Hemoglobin A1c (HbA1c) is the predominant diagnostic tool for diabetes diagnosis and progression.
However, it has proven to be insensitive at pre-diabetic threshold values. O-linked-β-N-acetylglucosamine (O-GlcNAc)
modification has emerged as a sensitive biomarker. The purpose of this study was to explore the sensitivity of O-GlcNAc
expression as a potential marker of early metabolic dysfunction in a young adult population. Healthy, young males
(18–35 y) from the Assessing Inherited Metabolic syndrome Markers in the Young study (AIMMY), were divided into
low (LH,0.60) or high (HH,1.61) homeostatic model assessment of insulin resistance (HOMA-IR) cohorts.
Findings: The relationships between a panel of anthropometric, metabolic measures and whole blood global protein
O-GlcNAc was examined. O-GlcNAc and O-GlcNAc transferase (OGT) levels were quantified by immunoblotting and
compared to anthropometric measures: body mass index (BMI), percentage body fat, aerobic fitness, blood glucose,
triglycerides, HDL, insulin, and HbA1c. HOMA-IR cohorts showed no differences in BMI, blood glucose or HbA1c, but
differed in percent body fat, plasma triglycerides, and circulating insulin. Greater O-GlcNAc expression was observed in
the whole blood of HH compared to LH. Moreover, a positive association between HOMA-IR and O-GlcNAc emerged,
while no relationship was found between HbA1c and HOMA-IR. This effect was not related to OGT expression.
Conclusions: Results indicate that O-GlcNAc has a greater sensitivity to metabolic status compared to HbA1c in this
population. O-GlcNAc has the potential to serve as a screening tool for predicting future metabolic disturbances in a
young healthy adult population free of any clinically relevant pathologies.
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Current estimates indicate there are 347 million diag-
nosed cases of diabetes worldwide, 90% of these being
attributable to type 2 diabetes (T2D) [1]. Research estab-
lishes that metabolic diseases, including T2D are often
initiated in childhood. In fact, the extent of metabolic
disease risk in children and young adults is correlated
with the presence of the same risk factors identified in
adults including obesity and insulin resistance [2].
At present, haemoglobin A1c (HbA1c) is the preferred
biomarker for diabetes diagnosis and monitoring; however,
this marker has proven to be insensitive at pre-diabetic
and diabetic threshold values [3]. As a result, there has* Correspondence: dbelke@ucalgary.ca
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unless otherwise stated.been an increased prevalence of undiagnosed diabetes,
thereby increasing the potential for complications. Re-
cently, the post-translational protein modification, O-
linked β-N-acetylglucosamine (O-GlcNAc), has emerged
as a potential biomarker for T2D. Protein O-GlcNAc is
the post-translational modification of intracellular proteins
by the addition or removal of O-GlcNAc mediated by
β-N-acetylglucosaminyltransferase (OGT) and β-N-
acetylglucosaminidase (OGA) in a manner analogous to
phosphorylation [4]. As the O-GlcNAc pathway utilizes
uridine diphosphate N-acetylglucosamine from the
hexosamine biosynthetic pathway, its study has been
closely linked to circulating glucose levels and diabetes,
where it is thought to play a role in mediating insulin
resistance [5,6].
Aberrant protein O-GlcNAc modification has been
associated with hyperglycemia, insulin resistance andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics and metabolic markers of
all subjects and stratified by low and high homeostatic







Age (years) 24 ± 1 24 ± 1 24 ± 1
Mean HOMA–IR 1.2 ± 0.2 0.5 ± 0.1 1.9 ± 0.2
BMI 24.7 ± 0.6 23.9 ± 0.8 25.5 ± 0.7
Body Fat (%) 16.3 ± 1.4 12.2 ± 0.9 20.3 ± 2.2*
Glucose (mM) 4.5 ± 0.1 4.6 ± 0.1 4.5 ± 0.1
Triglycerides (mM) 1.0 ± 0.1 0.8 ± 0.1 1.2 ± 0.1*
HDL Cholesterol (mM) 1.5 ± 0.1 1.7 ± 0.1 1.4 ± 0.1
Insulin (pM) 43.4 ± 6.0 19.8 ± 2.3 65.1 ± 6.6*
HbA1c (%) 5.5 ± 0.1 5.5 + 0.1 5.5 + 0.1
VO2 peak (20s)
(ml⋅kg−1⋅min−1)
49.1 ± 1.8 52.2 ± 2.4 45.7 ± 2.5
Abbreviations are as follows: body mass index (BMI, kg⋅m−2), high-density
lipoprotein cholesterol (HDL, mM), glycated hemoglobin (HbA1c, %), aerobic
capacity (VO2 peak, ml⋅kg
−1⋅min−1). Values are means ± SEM. *Indicates there is
a significant difference (p < 0.05) between low and high HOMA-IR groups.
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ined changes in the O-GlcNAc of erythrocytes and leu-
kocytes of healthy, pre-diabetic and overtly diabetic
adults in order to gain an enhanced understanding of
this modification as it relates to the development of the
disease [4,7,8]. These studies show that in overt dia-
betes, O-GlcNAc analysis has the potential to identify
metabolic disturbances better than HbA1c [7,8]. How-
ever, nothing is known about O-GlcNAc levels in a clin-
ically healthy young, asympotmatic adult population.
Study aims were to explore the relationships between a
panel of anthropometric and metabolic parameters with
whole blood O-GlcNAc, OGT and OGA in a sample of
healthy young adults.
Methods
Whole blood samples (n = 24) were collected from the
Assessing Inherited Markers of Metabolic Syndrome in
the Young (AIMMY) cohort at the University of Calgary
and approved by the Conjoint Health Research Ethics
Board (ID: E23521). Individual subjects were chosen
from the entire AIMMY cohort (n = 122) based on their
Homeostatic Model of Assessment – Insulin Resistance
(HOMA-IR) classification, being in either below lowest
(LL, P25, <0.845) or greatest (HH, P75, >1.61) quartiles
for this measure. HOMA-IR calculated as: [HOMA-IR =
[Fasting glucose (mmol · L−1) × fasting insulin (pmol)]/
22.5]. The inclusion criteria were 1) age 18–35 years, 2)
post-pubescent and 3) willing and able to provide in-
formed consent. All subjects were considered healthy as
previously outlined [9]. The study required subjects to
fast for 12 h prior to blood collection [9]. Body mass
index (BMI), percentage body fat (%), blood measures
including glucose, triglycerides, high density lipoprotein
cholesterol, insulin, and HbA1c were collected and ana-
lyzed as described [9].
Whole blood samples were collected and immediately
frozen. In preparation for immunoblotting, blood sam-
ples were homogenized in a lysis buffer (pH 7.4) consist-
ing of 20 mM NaCl, 20 mM Tris–HCl, 0.1 mM EDTA,
1% Triton X-100, 0.5% (wt./vol.) sodium deoxycholate,
and 0.1% β-mercaptoethanol (vol./vol.) in the presence
of phosphatase inhibitor, protease inhibitor, and PUG-
NAc (N-acetylhexosaminidase inhibitor, Sigma-Aldrich,
St. Louis, MO, A7229) to inhibit O-GlcNAcase activity.
Blood proteins were detected as previously described
[10,11]. Primary antibodies included anti-RL2 (1:1000;
Abcam, ab2739), anti-OGT (1:1000; DM-17 Sigma-
Aldrich, St. Louis, MO), and anti-OGA (1:1000; Santa Cruz
Biotech, sc-135093) with glyceraldehyde 3-phosphate
dehydrogenase (anti-GAPDH) (1:1000; Abcam, ab9485)
serving as a control. Secondary antibodies were as fol-
lows: anti-RL2: goat anti-mouse IgG HRP conj. (1:2000,
Thermo Scientific, 32430); and anti-OGT, anti-OGA,and anti-GAPDH: goat anti-rabbit IgG HRP (1:2000,
Cell Signaling Technology, 7074). Signals were detected
employing chemiluminesce (West Femto, Thermo Fisher
Scientific) and then exposed and analyzed using Syngene
ChemiGenius2 Bio Imaging System.
Subject characteristics and metabolic markers (Table 1,
Figure 1B) were compared employing independent t-
tests at a α = 0.05 significance level (SPSS Statistics V20).
The Pearson Product–moment Correlation Coefficient
was determined and compared to a critical value for a
two-tailed test (Figures 1C-E) [12]. All data are reported
as mean ± standard error of measurement (SEM).
Results
Subject characteristics are presented in Table 1. HOMA–
IR for the LH and HH group were 0.5 ± 0.1 and 1.9 ± 0.2
respectively. These values were much lower than the
widely adopted HOMA-IR cut-off of 2.60 for insulin re-
sistance [13]. No individuals were obese (BMI >30) or pre-
diabetic. The current diabetes diagnostic method, HbA1c,
was unable to distinguish the two groups, LH and HH,
with respect to insulin resistance (p > 0.05).
Global O-GlcNAc modification was greater in HH
compared to LH (p = 0.02) (Figure 1A, B). Results show
that this effect was not related to a difference in OGT
expression (Figure 1A) and we were unable to attain any
consistent OGA signal with immunoblotting, hence we
did not include these data. OGA has been shown to be
vulnerable to freeze thaw cycles [7,14], possibly explain-
ing why no signal was detected. All correlations are ex-
hibited in Figure 1C including the noteworthy positive
correlation between O-GlcNAc and HOMA-IR (r = 0.68,





Figure 1 Analysis of Blood for O-GlcNAc levels in Relation to Anthropometric Measurements. A) Analysis of whole blood comparing
subjects with low (LH) and high (HH) homeostatic model assessment for insulin resistance (HOMA-IR) for global O-GlcNAcylation (O-GlcNAc),
β-N-acetylglucosaminyltransferase (OGT), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in arbitrary units (AU). B) Quantification of
global O-GlcNAc for LH and HH. C) Linear regression analysis of O-GlcNAc and HOMA-IR. D) Linear regression analysis of body fat percentage (%)
and HOMA-IR. E) Linear regression analysis of O-GlcNAc and body fat percentage (%). All data represents n = 24. *Indicates p < 0.05.
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and triglycerides all had moderate to strong relationships
with HOMA-IR. The relationship between body fat per-
centage and HOMA-IR is shown in Figure 1D (r = 0.53,
p < 0.05). The relationship between O-GlcNAc and body
fat percentage is shown in Figure 1E (r = 0.14, p > 0.05).
There was no statistically significant difference in VO2
peak (20s) between LH and HH (p = 0.07), nor a rela-
tionship between O-GlcNAc and VO2 (Additional file 1:
Table S1).Discussion and conclusion
Many metabolic disease risk factors, including insulin re-
sistance begin to accumulate in young adulthood [15].
Consequently, there is an acute need to establish a sensi-
tive biomarker of diabetes prior to initiation of the disease
in this population. This study explored the relationship
between whole protein O-GlcNAc and HOMA-IR in a
healthy young adult population, free of any clinically
relevant pathology involving metabolism. O-GlcNAc
may be an ideal marker because intracellular O-GlcNAc
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trient sensing [16] and cellular protection [17]. In meta-
bolic disease states such as type 2 diabetes,
hyperglycemia drives O-GlcNAc and the chronic modi-
fication of selected proteins including those involved in
insulin signalling [18]. The chronic modification of cer-
tain proteins has also been linked to T2D aetiology and
progression [4,5,16].
Results of the present study show that O-GlcNAc
modification can be used to discriminate between LH
and HH in a young, healthy population. In contrast, no
differences were observed in HbA1c, the current diabetes
diagnostic gold standard. This suggests that that O-
GlcNAc analysis exhibits greater sensitivity and could
potentially serve as a better screening tool for identify-
ing the risk for future metabolic disturbances in a non-
overtly diabetic population. These results concur with
those of Springhorn et al. [8] who demonstrated that
leukocytes from both pre-diabetic and diabetic individ-
uals have elevated global O-GlcNAc compared to
healthy controls. The positive correlation between O-
GlcNAc and HOMA-IR suggests that the two indices
will continue to rise simultaneously but, due to unique
personal baseline measurements, determining a threshold
cut-off for identifying a given pathology is unrealistic. As
such, O-GlcNAc modification may be better utilized as a
screening tool and for individual monitoring.
The lack of difference in OGT expression suggests that
changes in O-GlcNAc modification are likely due to other
enzymatic activity, such as decreased OGA in the HH
group, or simply elevated circulating glucose levels and sub-
sequently increased flux through the hexosamine biosyn-
thetic pathway, which is associated with insulin resistance.
Biochemically, altered glucose metabolism is a requisite for
aberrant O-GlcNAc expression and, in general, nutritional
intake, whether it is fatty acid, nucleotide, or glucose, has
demonstrated an effect on O-GlcNAcylation as UDP-
GlcNAc, the donor molecular for O-GlcNAc, sits at the
nexus of these metabolic pathways [19]. As such, life-
style factors such as diet and exercise should be ex-
pected to play a key role in O-GlcNAc modification. In
the subjects examined, O-GlcNAc modification did not
correlate with VO2 max suggesting that O-GlcNAc modi-
fication does not provide insight into an individual’s aer-
obic capacity or pulmonary functional competence. To
date, relatively little is known regarding the effect of
chronic exercise on O-GlcNAc modification in blood to
help explain this relationship.
Given the lack of studies examining differences in pro-
tein O-GlcNAc in a young clinically healthy population,
especially with respect to susceptibility towards chronic
disease development later in life, our observations provide
a foundation for long-term studies of O-GlcNAc as a sensi-
tive screening tool for risk of future metabolic disturbances.We acknowledge the practical limitations associated with
administering protein O-GlcNAc quantification via immu-
noblot analysis to large populations, nonetheless this pre-
liminary research demonstrates the utility of O-GlcNAc
analysis as a screening tool. Moving forward, prospective
studies following O-GlcNAc modifications over time along
with changes in health status, insulin resistance, or the pro-
gression of diagnosed diabetes are warranted.
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